SecBot SecBot
8-K ·Filed May 6, 2026

TSHA

Taysha Gene Therapies, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001193125-26-207633
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on upcoming Part A data readout (Q2 2026) and REVEAL pivotal trial interim analysis, these binary catalysts will determine BLA filing feasibility. The widening net loss is expected for a pre-revenue biotech advancing toward registration, but the cash runway into 2028 provides a long enough window. Monitor for the Part A safety/efficacy data release expected within weeks.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Taysha Gene Therapies reported Q1 2026 financial results with a net loss of $42.4M ($0.12/share), wider than the $21.5M loss in Q1 2025, driven by increased R&D spending on BLA-enabling manufacturing and clinical trials. The key catalyst is the reaffirmed FDA alignment on the TSHA-102 BLA pathway, including potential submission based on the 6-month interim analysis from the REVEAL pivotal trial, with dosing completion expected in Q2 2026.

Key Financial Metrics

EPS
−$0.12
Rating
in line

Key Facts

  • Net loss of $42.4M ($0.12/share) for Q1 2026 vs $21.5M ($0.08/share) in Q1 2025
  • Cash and cash equivalents of $276.6M as of March 31, 2026, expected to fund operations into 2028
  • Reaffirmed FDA alignment on TSHA-102 BLA pathway, including potential submission based on 6-month interim analysis from REVEAL pivotal trial
  • Dosing completion in REVEAL pivotal and ASPIRE trials expected in Q2 2026
  • BLA-enabling PPQ campaign initiated in April 2026, completion expected in Q4 2026
  • No treatment-related SAEs or DLTs in all patients treated as of May 2026 data cutoff
  • R&D expenses increased to $33.8M from $15.6M year-over-year, driven by PPQ manufacturing and clinical trial costs

Financial Impact

Net loss widened by $20.9M year-over-year to $42.4M; cash burn rate increased significantly with R&D spending more than doubling

net losscash positionR&D expenses

Risk Factors

  • Clinical trial failure or disappointing efficacy data from Part A readout or REVEAL interim analysis
  • Regulatory setback or FDA request for additional data delaying BLA submission
  • Cash burn acceleration if PPQ campaign or clinical timelines extend beyond expectations
  • Dilution risk from ATM program or future equity offerings to fund commercial launch

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-207633
Document: d99032d8k.htm0001193125-26-207633
Document: 0001193125-26-207633-index-headers.html0001193125-26-207633
Document: 0001193125-26-207633-index.html0001193125-26-207633
Document: 0001193125-26-207633.txt0001193125-26-207633
8-K Data (Synthetic)0001193125-26-207633

Track record

14 reports on TSHA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 Viewing No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 5h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026